LianBio (LIAN) Competitors $0.23 -0.03 (-10.11%) As of 01/17/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends LIAN vs. NVCT, DBVT, INZY, TARA, MGX, ELUT, ENTA, IGMS, CABA, and MISTShould you be buying LianBio stock or one of its competitors? The main competitors of LianBio include Nuvectis Pharma (NVCT), DBV Technologies (DBVT), Inozyme Pharma (INZY), Protara Therapeutics (TARA), Metagenomi (MGX), Elutia (ELUT), Enanta Pharmaceuticals (ENTA), IGM Biosciences (IGMS), Cabaletta Bio (CABA), and Milestone Pharmaceuticals (MIST). These companies are all part of the "pharmaceutical products" industry. LianBio vs. Nuvectis Pharma DBV Technologies Inozyme Pharma Protara Therapeutics Metagenomi Elutia Enanta Pharmaceuticals IGM Biosciences Cabaletta Bio Milestone Pharmaceuticals Nuvectis Pharma (NASDAQ:NVCT) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends. Does the media prefer NVCT or LIAN? In the previous week, Nuvectis Pharma's average media sentiment score of 0.00 equaled LianBio'saverage media sentiment score. Company Overall Sentiment Nuvectis Pharma Neutral LianBio Neutral Does the MarketBeat Community prefer NVCT or LIAN? Nuvectis Pharma received 5 more outperform votes than LianBio when rated by MarketBeat users. Likewise, 90.00% of users gave Nuvectis Pharma an outperform vote while only 36.36% of users gave LianBio an outperform vote. CompanyUnderperformOutperformNuvectis PharmaOutperform Votes990.00% Underperform Votes110.00%LianBioOutperform Votes436.36% Underperform Votes763.64% Which has stronger valuation & earnings, NVCT or LIAN? Nuvectis Pharma is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvectis PharmaN/AN/A-$22.26M-$1.16-4.73LianBioN/AN/A-$110.29M-$0.81-0.29 Which has more volatility and risk, NVCT or LIAN? Nuvectis Pharma has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Comparatively, LianBio has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Do institutionals and insiders hold more shares of NVCT or LIAN? 96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 74.8% of LianBio shares are held by institutional investors. 35.8% of Nuvectis Pharma shares are held by company insiders. Comparatively, 7.6% of LianBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is NVCT or LIAN more profitable? LianBio's return on equity of -33.17% beat Nuvectis Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Nuvectis PharmaN/A -155.80% -104.02% LianBio N/A -33.17%-30.19% Do analysts prefer NVCT or LIAN? Nuvectis Pharma currently has a consensus price target of $21.00, suggesting a potential upside of 282.51%. Given Nuvectis Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Nuvectis Pharma is more favorable than LianBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvectis Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryNuvectis Pharma beats LianBio on 8 of the 12 factors compared between the two stocks. Get LianBio News Delivered to You Automatically Sign up to receive the latest news and ratings for LIAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIAN vs. The Competition Export to ExcelMetricLianBioBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.28M$176.53M$5.34B$9.11BDividend YieldN/A3.64%5.37%4.00%P/E Ratio-0.29132.0357.4913.22Price / SalesN/A19,219.461,275.6876.05Price / CashN/A13.0136.6032.90Price / Book0.099.264.874.58Net Income-$110.29M-$20.89M$118.05M$224.84M7 Day Performance-10.07%0.30%1.50%2.37%1 Month Performance-11.74%1.87%2.55%4.40%1 Year Performance-94.27%130.78%25.83%20.11% LianBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIANLianBioN/A$0.23-10.1%N/A-94.3%$25.28MN/A-0.29110NVCTNuvectis Pharma2.9906 of 5 stars$5.81flat$21.00+261.4%-33.0%$112.26MN/A-5.018Positive NewsDBVTDBV Technologies3.609 of 5 stars$5.41+8.9%$22.50+315.9%-46.1%$111.28M$15.73M-1.2080INZYInozyme Pharma3.4605 of 5 stars$1.72-14.0%$18.33+965.9%-68.4%$110.49MN/A-1.1050Short Interest ↑Gap UpTARAProtara Therapeutics2.5454 of 5 stars$5.31-4.5%$22.67+326.9%+138.2%$109.55MN/A-1.8830MGXMetagenomi1.6562 of 5 stars$2.91-7.0%$16.67+472.7%N/A$108.90M$55.08M0.00236Positive NewsGap DownELUTElutia3.1088 of 5 stars$3.13-4.0%$10.00+219.5%-19.8%$108.18M$24.78M-1.20180Positive NewsGap DownENTAEnanta Pharmaceuticals4.1067 of 5 stars$5.03-1.2%$17.25+242.9%-55.2%$106.61M$67.64M-0.92160Positive NewsGap DownIGMSIGM Biosciences4.6968 of 5 stars$1.78-14.8%$5.50+209.0%-83.2%$105.85M$2.92M-0.49190Gap UpCABACabaletta Bio3.0437 of 5 stars$2.16+3.8%$24.38+1,028.5%-85.9%$105.57MN/A-1.0050MISTMilestone Pharmaceuticals2.382 of 5 stars$1.97-5.3%$13.00+559.9%+41.4%$105.06M$1M-2.4330 Related Companies and Tools Related Companies NVCT Alternatives DBVT Alternatives INZY Alternatives TARA Alternatives MGX Alternatives ELUT Alternatives ENTA Alternatives IGMS Alternatives CABA Alternatives MIST Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LIAN) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LianBio Please log in to your account or sign up in order to add this asset to your watchlist. Share LianBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
